Recent events
Recent events tied to this brand in public sources.
Back to profile2 entries
2021
FDA approves Verkazia for vernal keratoconjunctivitis
The FDA approved a new drug application for Verkazia to treat vernal keratoconjunctivitis in children and adults, according to a press release from Santen Pharmaceutical Co.
2020
Santen Completes Acquisition of Eyevance
Santen acquired all outstanding shares of Eyevance for $225 million in cash, making Eyevance a wholly owned subsidiary. VISOVANQ and NEXAGON were excluded from the purchase.